Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 20,000 Shares of Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 20,000 shares of Alpha Tau Medical stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $12.00, for a total transaction of $240,000.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at approximately $1,082,160. This trade represents a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total transaction of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Stock Up 0.5%

DRTS stock opened at $12.64 on Thursday. The stock’s 50 day simple moving average is $9.64 and its 200 day simple moving average is $7.79. Alpha Tau Medical Ltd. has a fifty-two week low of $2.87 and a fifty-two week high of $13.06. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The company has a market cap of $1.14 billion, a P/E ratio of -18.87 and a beta of 1.16.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings data on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). On average, research analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Trifecta Capital Advisors LLC bought a new position in Alpha Tau Medical during the 4th quarter valued at $48,000. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical in the 3rd quarter worth $62,000. Principal Financial Group Inc. purchased a new stake in shares of Alpha Tau Medical in the first quarter valued at about $132,000. Bank of America Corp DE raised its holdings in shares of Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Alpha Tau Medical by 291.7% during the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares in the last quarter. 2.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on DRTS. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. Citigroup raised their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Piper Sandler lifted their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a report on Tuesday, May 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. Finally, Barclays raised their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Alpha Tau Medical has a consensus rating of “Hold” and an average target price of $12.60.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.